- Home
- RCEL vs NAUT Comparison
RCEL vs NAUT Comparison
Compare RCEL & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- NAUT
- Stock Information
- Founded
- RCEL N/A
- NAUT 2016
- Country
- RCEL United States
- NAUT United States
- Employees
- RCEL N/A
- NAUT N/A
- Industry
- RCEL Medical/Dental Instruments
- NAUT Biotechnology: Laboratory Analytical Instruments
- Sector
- RCEL Health Care
- NAUT Industrials
- Exchange
- RCEL Nasdaq
- NAUT Nasdaq
- Market Cap
- RCEL 113.7M
- NAUT 95.6M
- IPO Year
- RCEL N/A
- NAUT N/A
- Fundamental
- Price
- RCEL $4.56
- NAUT $0.72
- Analyst Decision
- RCEL Strong Buy
- NAUT Strong Sell
- Analyst Count
- RCEL 4
- NAUT 1
- Target Price
- RCEL $13.75
- NAUT $1.75
- AVG Volume (30 Days)
- RCEL 282.4K
- NAUT 250.4K
- Earning Date
- RCEL 11-06-2025
- NAUT 10-28-2025
- Dividend Yield
- RCEL N/A
- NAUT N/A
- EPS Growth
- RCEL N/A
- NAUT N/A
- EPS
- RCEL N/A
- NAUT N/A
- Revenue
- RCEL $74,884,000.00
- NAUT N/A
- Revenue This Year
- RCEL $28.23
- NAUT N/A
- Revenue Next Year
- RCEL $35.24
- NAUT N/A
- P/E Ratio
- RCEL N/A
- NAUT N/A
- Revenue Growth
- RCEL 38.32
- NAUT N/A
- 52 Week Low
- RCEL $3.60
- NAUT $0.62
- 52 Week High
- RCEL $14.16
- NAUT $3.09
- Technical
- Relative Strength Index (RSI)
- RCEL 46.58
- NAUT 54.09
- Support Level
- RCEL $4.12
- NAUT $0.70
- Resistance Level
- RCEL $4.44
- NAUT $0.73
- Average True Range (ATR)
- RCEL 0.25
- NAUT 0.04
- MACD
- RCEL 0.03
- NAUT 0.01
- Stochastic Oscillator
- RCEL 50.00
- NAUT 77.46
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.